What is a peptide certificate of analysis (COA)?
A peptide certificate of analysis is a controlled document that records the analytical testing performed on a specific manufactured batch and the results obtained against defined acceptance criteria. It is batch-specific, not product-generic: a COA references a unique lot or batch identifier, a manufacture or test date, and the analytical methods applied. Reading experimental material critically — treating each figure as evidence that must be interrogated rather than accepted at face value — is a discipline long recognised in the information and documentation literature (DOI:10.1002/asi.5090180408). A robust COA typically presents several distinct data blocks: a header identifying the material, sequence and molecular formula; an appearance or physical description; an HPLC purity result with associated chromatogram; a mass spectrometry identity result; and quantitative fields such as net peptide content, water content and counterion (for example, trifluoroacetate) level. The value of the document lies in traceability. Each reported number should map back to a raw instrument output, and the method conditions should be stated so that the result is reproducible and interpretable. When reviewing a COA for research-use material in Australia, first confirm that the batch identifier on the document matches the physical vial label. A mismatch, a missing method description, or a purity value with no supporting chromatogram are all reasons to seek clarification before the material is catalogued into a laboratory inventory. Documentation systems function best when metadata is complete and discoverable, a principle reinforced by data-management frameworks that emphasise findability and provenance of records (DOI:10.3897/tdwgproceedings.1.19941). A COA is therefore both an analytical summary and an audit artefact.
How do you read an HPLC purity chromatogram?
Reversed-phase HPLC (RP-HPLC) is the workhorse purity method for synthetic peptides, and the chromatogram is the visual heart of the COA. The x-axis shows time (retention time, in minutes) and the y-axis shows detector response, usually UV absorbance at a wavelength such as 214 nm (amide bond absorbance) or 220 nm. The main peptide elutes as the dominant peak; its retention time should be consistent between the batch and any reference run. Purity is normally reported as area percent: the area under the main peak divided by the total integrated area of all peaks, expressed as a percentage. Read the number alongside the trace — a stated 98% purity should correspond to a chromatogram where the main peak visually dominates and impurity peaks are small. Check the gradient conditions (mobile phase A and B composition, typically water and acetonitrile with an acid modifier), the column chemistry (commonly C18), flow rate and injection details, because these determine separation quality. HPLC is a quantitative separation technique whose accuracy depends on well-resolved, baseline-separated peaks and correct integration, as demonstrated in direct HPLC assay methodology (DOI:10.1006/abio.1993.1102). When interpreting results, watch for co-eluting shoulders, baseline drift, and integration boundaries that may exclude minor impurities. A single high-purity figure without a visible, well-integrated chromatogram is difficult to verify. Confirm that the integration table lists retention times and area percentages for each detected peak, and that these sum consistently. In an Australian research setting, retaining the full chromatogram — not just the summary number — supports later re-analysis and QC record-keeping.
What does peak purity assessment tell you?
Area-percent purity assumes that the main chromatographic peak represents a single component. Peak purity assessment tests that assumption. A peak that looks symmetrical on a UV-absorbance trace can still hide a co-eluting impurity with a similar retention time. Diode-array detection (DAD, also called photodiode array or PDA) addresses this by collecting a full UV spectrum across the peak rather than at one wavelength. If the spectral profile is identical at the leading edge, apex and trailing edge, the peak is spectrally homogeneous — evidence, though not proof, that it is a single component. If spectra differ across the peak, co-elution is likely and the reported purity may overstate true composition. On a COA, peak purity may appear as a purity angle versus purity threshold, a purity factor, or a match-quality index depending on the software. Values within threshold indicate no detected spectral heterogeneity at the method's sensitivity. Interpreting these outputs requires care: a passing peak purity result is conditional on the method's ability to separate and spectrally distinguish impurities, so it should be read together with the gradient and column information rather than in isolation. The broader principle — that a reported result must be interpreted in the context of its method and its limitations — mirrors guidance on critically appraising analytical and research reports (DOI:10.5694/j.1326-5377.1992.tb137249.x). When a COA includes a peak purity figure, note whether DAD was used and what wavelength range was scanned. Where only single-wavelength UV is reported, peak purity cannot be inferred from the chromatogram alone, and orthogonal confirmation via mass spectrometry becomes more important for a complete picture.
How does mass spectrometry confirm peptide identity on a COA?
HPLC establishes how pure a sample is, but it does not by itself confirm that the main peak is the intended peptide. Mass spectrometry (MS), commonly electrospray ionisation MS (ESI-MS), supplies the identity evidence. The COA states a theoretical (calculated) monoisotopic or average molecular weight derived from the peptide sequence, and an observed value from the instrument. For a correct identity, the observed mass should match the theoretical mass within the method's tolerance. ESI frequently produces multiply-charged ions, so the raw spectrum may show several m/z peaks (for example [M+H]+, [M+2H]2+, [M+3H]3+) that deconvolute to one neutral mass; a well-prepared COA reports the deconvoluted result and may show the raw spectrum. Read the mass agreement first: a match within a few daltons (or better) supports identity, while a systematic offset can indicate a sequence deletion, an unexpected modification, or an adduct. Where the report includes tandem MS (MS/MS) fragment data, sequence-specific b- and y-ions provide finer confirmation of the amino acid order. Combining a purity technique with an orthogonal identity technique is the standard analytical logic for peptide release documentation, echoing the value of applying complementary methods to characterise a sample (DOI:10.1006/abio.1993.1102). On the COA, cross-check that the sequence, molecular formula and calculated mass are internally consistent. If the calculated mass does not correspond to the stated sequence, the document has a transcription or calculation error that should be resolved before the material is used. Identity confirmation and purity assessment are separate questions, and a complete COA answers both.
How do net peptide content and counterion data affect quantification?
Two quantitative fields on a peptide COA are frequently overlooked yet materially affect how much peptide a vial actually contains: net peptide content and counterion (salt) level. Synthetic peptides are typically isolated as salts — most often trifluoroacetate (TFA) from purification — and lyophilised material also retains bound water. The gross mass in a vial therefore includes peptide, counterion and residual moisture. Net peptide content, usually determined by amino acid analysis or quantitative HPLC against a reference, reports the actual proportion that is peptide, commonly expressed as a percentage. A vial with high HPLC area-percent purity can still have a moderate net peptide content once salt and water are subtracted, because purity (relative composition of the peptide fraction) and content (absolute peptide mass) measure different things. Read these fields together: HPLC purity tells you how clean the peptide is; net content tells you how much of the vial mass is that peptide. Counterion analysis, often by ion chromatography or fluorine-specific methods, quantifies residual TFA. Water content is typically measured by Karl Fischer titration. For accurate concentration calculations in a research protocol, quantification should be based on net peptide content rather than nominal vial mass. This distinction is central to careful data interpretation — reading a result for what it actually measures rather than what the headline implies, a discipline emphasised across guidance on interpreting reported figures (DOI:10.7816/ulakbilge-05-15-06). A complete Australian research COA that lists purity, net content, counterion and water content allows the reviewer to reconcile all quantitative claims and document them for traceable record-keeping.
What documentation and traceability should accompany a COA in Australia?
Beyond the individual analytical results, a COA sits within a wider documentation system, and its quality depends on how well that system links records together. For research peptides handled in Australia, sound documentation practice means the COA carries an unambiguous batch or lot identifier that appears on the vial label, the shipping paperwork and any internal inventory record, so that a physical sample can always be traced to its analytical file. The document should state the testing laboratory, the analytical methods used (with enough method detail to interpret each result), test dates, and the acceptance criteria the batch was evaluated against. Where storage and handling conditions are relevant to stability, the documentation set may reference recommended storage temperature and reconstitution guidance held in separate controlled records. Findability and complete metadata are recognised prerequisites for reliable scientific documentation systems, where records must be discoverable and their provenance clear (DOI:10.3897/tdwgproceedings.1.19941). A practical review workflow is: confirm identifiers match; verify each headline number against its supporting trace or table; check method conditions are present; reconcile purity, identity, net content and counterion fields for internal consistency; and file the full COA with the batch record rather than retaining only a summary. Treating the COA as a source document to be critically read — not a marketing figure to be trusted — aligns with long-standing guidance on appraising experimental and reported material (DOI:10.1002/asi.5090180408). Well-maintained documentation supports reproducibility, audit readiness and confident QC decisions across a research programme, and it is the reviewer's responsibility to ensure the record is complete before the material is entered into use.
Apply this checklist to documented stock
You now have a practical way to read purity figures, method notes, and lot traceability. When you source materials, hold suppliers to that same checklist — ClaraScience issues batch documentation with every order and dispatches from Australian warehouses with Express tracked shipping.
Start with a retail order to review documentation end-to-end, or register for wholesale if you restock multiple compounds.
Frequently asked questions
What is the difference between HPLC purity and net peptide content?
HPLC purity is a relative measure — the main peak's area as a percentage of total peak area — describing how clean the peptide fraction is. Net peptide content is an absolute measure of how much of the vial mass is actually peptide, after subtracting counterion salt and residual water. A batch can show high purity yet moderate net content; both should be read together.
Why does a mass spectrometry spectrum show several peaks for one peptide?
Electrospray ionisation often produces multiply-charged ions, so a single peptide can appear as several m/z signals such as [M+H]+, [M+2H]2+ and [M+3H]3+. Software deconvolutes these into one neutral molecular weight. A well-prepared COA reports that deconvoluted mass and compares it to the theoretical mass calculated from the sequence.
What is peak purity and why does it matter on a COA?
Peak purity assessment uses diode-array detection to compare UV spectra across a chromatographic peak. If spectra match at the leading edge, apex and trailing edge, the peak is spectrally homogeneous, indicating no detected co-elution. It matters because a symmetrical single-wavelength peak can still hide an impurity with a similar retention time.
What does the counterion figure on a peptide COA mean?
Synthetic peptides are often isolated as salts, commonly trifluoroacetate (TFA) from purification. The counterion figure quantifies residual salt, typically by ion chromatography or a fluorine-specific method. Because counterion and water add to vial mass, this value helps explain the gap between gross mass and net peptide content for accurate quantification.
How should a batch identifier be checked against a COA?
The batch or lot identifier on the COA should match the vial label, shipping documentation and any inventory record exactly. A mismatch, a missing identifier, or a purity value with no supporting chromatogram are reasons to seek clarification before entering the material into a research workflow, since traceability underpins reliable documentation.
References
- DOI:10.1002/asi.5090180408 — Suggestions on how to read experimental material in information science — American Documentation — 1967
- DOI:10.1006/abio.1993.1102 — The Direct Assay of Kinases and Acyl-CoA Synthetases by HPLC: Application to Nucleoside Diphosphate Kinase and Succinyl-CoA Synthetase — Analytical Biochemistry — 1993
- DOI:10.3897/tdwgproceedings.1.19941 — Documentation about Atlas of Living Australia tools: how to find information — Proceedings of TDWG — 2017
- DOI:10.5694/j.1326-5377.1992.tb137249.x — 13. How to read a journal article — Medical Journal of Australia — 1992
- DOI:10.7816/ulakbilge-05-15-06 — HOW TO BE READ PIAAC RESULTS FOR ADAPTATION TO NEW AGE? — Ulakbilge Dergisi — 2017
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
